This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 108.5%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 108.5% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
by Zacks Equity Research
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.